Spread & Containment
Treasury To Cut Auction Sizes More Than Expected
Treasury To Cut Auction Sizes More Than Expected
The US Treasury said on Wednesday, just hours before the Fed unveils its balance sheet-busting…

The US Treasury said on Wednesday, just hours before the Fed unveils its balance sheet-busting Quantitative Tightening, that it trimmed its quarterly sale of longer-term debt for a third straight quarter (with the largest cuts coming in the seven-year and 20-year maturities) and also warned that it may make further reductions, citing “strong” federal tax revenues.
The Treasury said it was trimming issuance by smaller increments than in previous quarters based on projected funding needs that include strong tax receipts and potential redemptions of Treasury securities as par tof the Fed's QT.
Specifically, the Treasury announces refunding debt sales next week totaling $103BN, down $7BN from $110BN in February, to refund approximately $47.8 billion of privately-held Treasury notes maturing on May 15, 2022 and plans to reduce sizes for all fixed-rate nominal auctions during the quarter. This marks the longest string of quarterly cuts since a 2014-2015 cycle. In a surprise for some dealers, it’s also trimming sales of two-year, three-year and five-year auctions in coming months (see below). The refunding issuance will raise new cash of approximately $55.2 billion; the details are as follows:
- Treasury to sell $45b of 3-year notes on May 10, down $5BN from the Feb refunding
- Treasury to sell $36b of 10-year notes on May 11, down $1BN from the Feb refunding
- Treasury to sell $22b of 30-year bonds on May 12, the same amount as the Feb refunding.
Next week's $103BN refunding is the smallest since May 2020, and compares with a peak of $126BN first reached in February 2021; auction sizes across the curve began rising in 2018 to finance tax cuts and surged in 2020 to finance federal pandemic response
Over the next three months, the Treasury anticipates incrementally reducing the size of each of the 2-, 3-, and 5-year note auctions by $1 billion per month. As a result, the size of the 2-, 3-, and 5-year note auctions will each decrease by $3 billion by the end of July. Treasury also anticipates reducing the size of the 7-year note auction by $2 billion per month. As a result, the size of the 7-year note auction will decrease by $6 billion by the end of July. Treasury also anticipates decreases of $1 billion to both the new and reopened 10-year note auction sizes and to the new and reopened 30-year bond auction sizes starting in May. Treasury also anticipates decreases of $2 billion to both the new and reopened 20-year bond auction sizes starting in May. For the 20-year bond, Treasury announced sizes of $17b/$14b/$14b for new issue and reopenings; dealer estimates ranged from unchanged ($19b/$16b/$16b) to as low as $15b/$12b/$12b over May, June and July. In addition, Treasury anticipates maintaining the May and June reopening 2-year FRN auction sizes and maintaining the July new issue 2-year FRN auction size.
Or visually:
Separately, changes in nominal and FRN auction sizes will reduce issuance to private investors by $69b compared to the previous quarter. TIPS auctions during the quarter will include a $14b 10-year reopening in May, an $18b 5-year reopening in June and a $17b 10-year new issue in July. The June 5-year TIPS reopening and the July 10-year TIPS new issue will each increase by $1BN.
“Given Treasury’s desire to stabilize the share of TIPS as a percent of total marketable debt outstanding and continued robust demand, Treasury will continue to monitor TIPS market conditions and consider whether subsequent modest increases would be appropriate,” Treasury says.
The Treasury said on Monday it expects to pay down $26 billion in debt the second quarter, down from a January borrowing estimate of $66 billion, primarily because of an increase in receipts. The second-quarter estimate assumes an end-of-June cash balance of $800 billion.
As Bloomberg notes, dealers had widely expected the reduction to next week’s sale of notes and bonds, but viewed it as likely to be the last cutback ahead of the Federal Reserve’s move to shrink its $5.8 trillion stockpile of Treasuries. The Fed is forecast to unveil its bond-portfolio runoff plan later on Wednesday, and that process was seen forcing the Treasury to have to sell more debt to the public.
The U.S. government had increased auction sizes in 2020 to pay for coronavirus-related spending; however, since November 2021, Treasury has made substantial progress towards aligning issuance with intermediate-term borrowing needs by reducing auction sizes across all nominal coupon securities. During this period, it said it "also received important information regarding Treasury’s projected borrowing needs, most notably recent strong tax receipts and public communications from the Federal Open Market Committee regarding potential redemptions of Treasury securities from the Federal Reserve System Open Market Account (SOMA)."
Based on this updated information, "Treasury intends to continue reducing auction sizes of nominal coupon securities during the upcoming May – July 2022 quarter, though by smaller increments than in previous quarters. While the issuance plans announced today leave Treasury well positioned to finance additional privately-held net marketable borrowing needs resulting from potential SOMA redemptions and to address potential changes to the fiscal outlook, additional reductions in future quarters may be necessary depending on future developments in projected borrowing needs", the Treasury said, referring to the Fed's intention to stop rolling over all of the maturing Treasury securities in its System Open Market Account
Treasury plans to address any seasonal or unexpected variations in borrowing needs over the next quarter through changes in regular bill auction sizes and/or CMBs.
There was another surprise announcement: regarding bills, the Treasury said it plans to change the 4-month cash management bill into a weekly benchmark offering, with details to be provided at the August refunding announcement. Some more details:
Given the outlook for T-bill supply over the intermediate to long term and after gathering feedback from a variety of market participants, including the primary dealers and the Treasury Borrowing Advisory Committee, later this year Treasury intends to change the 4-month (i.e., 17-week) CMB into a benchmark bill (part of the regular weekly bill issuance schedule going forward). Investor reception to the 4-month CMB has been strong, and elevation to benchmark status will further support demand.
Over the coming months, Treasury plans to make necessary operational and systems changes in order to smoothly transition the 4-month CMB to benchmark status. During this transition, Treasury will continue to issue the 4-month CMB at a regular cadence. Treasury also intends to maintain the Tuesday settlement and maturity cycle when the 4-month CMB becomes a benchmark bill. Additional implementation details, including the likely timing of the first benchmark auction, will be provided at the August quarterly refunding.
Looking ahead, the Treasury made two preview announcement: i) it intends to issue in the coming months a request for information about possible steps to improve transparency for secondary market transactions in its securities and encourages market participants and the broader public to respond; and ii) the Treasury is planning amendments to auction regulations in coming months, including an increase in the non- competitive bidding and award limits for all securities to $10MM from $5MM in light of growth in auction sizes.
Separately, the minutes of the all-important Treasury Borrowing Advisory Committee (TBAC) latest meeting indicated the following:
- In light of the strength in federal tax receipts, as well as the prospect for Federal Reserve balance sheet reductions, the Committee recommended that Treasury should continue with coupon auction size reductions across tenors during the upcoming refunding quarter, with slightly larger reductions in the 7-year note and 20-year bond, but at a slower pace than cuts announced in November and February
- They noted reductions to nominal coupon issuance would likely maintain the share of bills within, but toward the lower end of, its recommended 15%-20% range over time
- Committee emphasized the need for Treasury to remain nimble in its debt management decisions, given the ongoing uncertainty in borrowing needs
- Also said the strength in receipts should be monitored to determine if it is “more of an anomaly or a trend that could warrant additional cut to coupons in the subsequent quarters”
- Committee heard a presentation on Treasury market trading conditions since the beginning of the year and how evolving inflation and monetary policy expectations, as well as heightened geopolitical tensions affected market volatility and liquidity
- Presenting member stated that while liquidity conditions since the beginning of the year appeared worse based on some metrics, other metrics showed no significant deterioration, and funding markets were functioning properly and weren’t a factor in strained liquidity conditions
- Lower liquidity was largely due to elevated volatility as a result of the elevated uncertainty around the inflation, monetary policy, and geopolitical outlook
- Committee then discussed the presentation, with several members noting that liquidity conditions could also be affected by the Federal Reserve’s balance sheet reduction
- TBAC then turned to a presentation on the four-month, or 17-week cash management bill (CMB)
- Presenting member noted that Treasury should take into account the trajectory of future bill issuance, current and future demand for the 4-month CMB compared to benchmark bills, and whether this benchmark offering would complement the current debt management process
- Based on the projected growth in bill issuance in the longer term, strong expected future demand, and the compatibility of the 4-month bill issuance patterns and maturities for both investors and Treasury, the presenting member recommended that Treasury should consider moving the 4-month CMB to benchmark status
- The Committee unanimously supported the recommendation to make the 4-month bill a benchmark tenor
In response to the Refunding announcement, Treasuries did, well... nothing, holding on to gains across belly and long-end of the curve.
The 5s30s curve was around -2.2bp, remaining flatter by 0.7bp on the day, while 2s10s spread extends flattening slightly to 3bp tighter on the day. U.S. yields remain ~1bp richer across long-end of the curve with front-end underperforming, with 2- year yields cheaper by ~3bp on the day. In the long-end the 10s20s30s fly is steady around 45bp, little changed on the day after the refunding announcement.
International
Repeated COVID-19 Vaccination Weakens Immune System: Study
Repeated COVID-19 Vaccination Weakens Immune System: Study
Authored by Zachary Stieber via The Epoch Times (emphasis ours),
Repeated COVID-19…

Authored by Zachary Stieber via The Epoch Times (emphasis ours),
Repeated COVID-19 vaccination weakens the immune system, potentially making people susceptible to life-threatening conditions such as cancer, according to a new study.
Multiple doses of the Pfizer or Moderna COVID-19 vaccines lead to higher levels of antibodies called IgG4, which can provide a protective effect. But a growing body of evidence indicates that the “abnormally high levels” of the immunoglobulin subclass actually make the immune system more susceptible to the COVID-19 spike protein in the vaccines, researchers said in the paper.
They pointed to experiments performed on mice that found multiple boosters on top of the initial COVID-19 vaccination “significantly decreased” protection against both the Delta and Omicron virus variants and testing that found a spike in IgG4 levels after repeat Pfizer vaccination, suggesting immune exhaustion.
Studies have detected higher levels of IgG4 in people who died with COVID-19 when compared to those who recovered and linked the levels with another known determinant of COVID-19-related mortality, the researchers also noted.
A review of the literature also showed that vaccines against HIV, malaria, and pertussis also induce the production of IgG4.
“In sum, COVID-19 epidemiological studies cited in our work plus the failure of HIV, Malaria, and Pertussis vaccines constitute irrefutable evidence demonstrating that an increase in IgG4 levels impairs immune responses,” Alberto Rubio Casillas, a researcher with the biology laboratory at the University of Guadalajara in Mexico and one of the authors of the new paper, told The Epoch Times via email.
The paper was published by the journal Vaccines in May.
Pfizer and Moderna officials didn’t respond to requests for comment.
Both companies utilize messenger RNA (mRNA) technology in their vaccines.
Dr. Robert Malone, who helped invent the technology, said the paper illustrates why he’s been warning about the negative effects of repeated vaccination.
“I warned that more jabs can result in what’s called high zone tolerance, of which the switch to IgG4 is one of the mechanisms. And now we have data that clearly demonstrate that’s occurring in the case of this as well as some other vaccines,” Malone, who wasn’t involved with the study, told The Epoch Times.
“So it’s basically validating that this rush to administer and re-administer without having solid data to back those decisions was highly counterproductive and appears to have resulted in a cohort of people that are actually more susceptible to the disease.”
Possible Problems
The weakened immune systems brought about by repeated vaccination could lead to serious problems, including cancer, the researchers said.
Read more here...
Spread & Containment
Robert F. Kennedy Jr. Banned By Major Social Media Site, Campaign Pages Blocked
Robert F. Kennedy Jr. Banned By Major Social Media Site, Campaign Pages Blocked
Authored by Jack Phillips via The Epoch Times (emphasis ours),
Twitter…

Authored by Jack Phillips via The Epoch Times (emphasis ours),
Twitter owner Elon Musk invited Democrat presidential candidate Robert F. Kennedy Jr. for a discussion on his Twitter Spaces after Kennedy said his campaign was suspended by Meta-owned Instagram.
“Interesting… when we use our TeamKennedy email address to set up @instagram accounts we get an automatic 180-day ban. Can anyone guess why that’s happening?” he wrote on Twitter.
An accompanying image shows that Instagram said it “suspended” his “Team Kennedy” account and that there “are 180 days remaining to disagree” with the company’s decision.
In response to his post, Musk wrote: “Would you like to do a Spaces discussion with me next week?” Kennedy agreed, saying he would do it Monday at 2 p.m. ET.
Hours later, Kennedy wrote that Instagram “still hasn’t reinstated my account, which was banned years ago with more than 900k followers.” He argued that “to silence a major political candidate is profoundly undemocratic.”
“Social media is the modern equivalent of the town square,” the candidate, who is the nephew of former President John F. Kennedy, wrote. “How can democracy function if only some candidates have access to it?”
The Epoch Times approached Instagram for comment.
Interesting… when we use our TeamKennedy email address to set up @instagram accounts we get an automatic 180-day ban. Can anyone guess why that’s happening? pic.twitter.com/0G8oRnoXTv
— Robert F. Kennedy Jr (@RobertKennedyJr) June 2, 2023
It’s not the first time that either Facebook or Instagram has taken action against Kennedy. In 2021, Instagram banned him from posting claims about vaccine safety and COVID-19.
After he was banned by the platform, Kennedy said that his Instagram posts raised legitimate concerns about vaccines and were backed by research. His account was banned just days after Facebook and Instagram announced they would block the spread of what they described as misinformation about vaccines, including research saying the shots cause autism, are dangerous, or are ineffective.
“This kind of censorship is counterproductive if our objective is a safe and effective vaccine supply,” he said at the time.
Read more here...
International
Study Falsely Linking Hydroxychloroquine To Increased Deaths Frequently Cited Even After Retraction
Study Falsely Linking Hydroxychloroquine To Increased Deaths Frequently Cited Even After Retraction
Authored by Jessie Zhang via Thje Epoch…

Authored by Jessie Zhang via Thje Epoch Times (emphasis ours),
An Australian and Swedish investigation has found that among the hundreds of COVID-19 research papers that have been withdrawn, a retracted study linking the drug hydroxychloroquine to increased mortality was the most cited paper.
With 1,360 citations at the time of data extraction, researchers in the field were still referring to the paper “Hydroxychloroquine or chloroquine with or without a macrolide for treatment of COVID-19: a multinational registry analysis” long after it was retracted.
Authors of the analysis involving the University of Wollongong, Linköping University, and Western Sydney Local Health District wrote (pdf) that “most researchers who cite retracted research do not identify that the paper is retracted, even when submitting long after the paper has been withdrawn.”
“This has serious implications for the reliability of published research and the academic literature, which need to be addressed,” they said.
“Retraction is the final safeguard against academic error and misconduct, and thus a cornerstone of the entire process of knowledge generation.”
Scientists Question Findings
Over 100 medical professionals wrote an open letter, raising ten major issues with the paper.
These included the fact that there was “no ethics review” and “unusually small reported variances in baseline variables, interventions and outcomes,” as well as “no mention of the countries or hospitals that contributed to the data source and no acknowledgments to their contributions.”

Other concerns were that the average daily doses of hydroxychloroquine were higher than the FDA-recommended amounts, which would present skewed results.
They also found that the data that was reportedly from Australian patients did not seem to match data from the Australian government.
Eventually, the study led the World Health Organization to temporarily suspend the trial of hydroxychloroquine on COVID-19 patients and to the UK regulatory body, MHRA, requesting the temporary pause of recruitment into all hydroxychloroquine trials in the UK.
France also changed its national recommendation of the drug in COVID-19 treatments and halted all trials.
Currently, a total of 337 research papers on COVID-19 have been retracted, according to Retraction Watch.
Further retractions are expected as the investigation of proceeds.
-
Spread & Containment4 hours ago
Robert F. Kennedy Jr. Banned By Major Social Media Site, Campaign Pages Blocked
-
International7 hours ago
Study Falsely Linking Hydroxychloroquine To Increased Deaths Frequently Cited Even After Retraction
-
Spread & Containment14 hours ago
Mark Zuckerberg Moves to Kill a Pandemic Habit
-
International15 hours ago
Complying, Not Defying: Twitter And The EU Censorship Code
-
Government10 hours ago
Biden Signs Debt Ceiling Bill, Ending Monthslong Political Battle
-
Uncategorized7 hours ago
Warren Buffett’s Advice on Stocks vs. Bonds
-
Spread & Containment11 hours ago
Mark Zuckerberg Makes a Bold Move
-
International3 hours ago
Repeated COVID-19 Vaccination Weakens Immune System: Study